The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

Abstract Oncotype DX (ODX) recurrence score (RS) is a validated tool to guide the use of adjuvant chemotherapy (AC) in hormone receptor+/HER2- breast cancer. In this analysis, we examine (1) characteristics associated with ODX testing and (2) the association between ODX RS and receipt of AC across a...

Full description

Bibliographic Details
Main Authors: Kathleen Iles, Mya L. Roberson, Philip Spanheimer, Kristalyn Gallagher, David W. Ollila, Paula D. Strassle, Stephanie Downs-Canner
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00394-1

Internet

https://doi.org/10.1038/s41523-022-00394-1

Similar Items